ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 67 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q3 2013. The put-call ratio across all filers is 22.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $18,000 | -18.2% | 48,944 | 0.0% | 0.00% | – |
| Q1 2017 | $22,000 | -8.3% | 48,944 | 0.0% | 0.00% | – |
| Q4 2016 | $24,000 | -4.0% | 48,944 | 0.0% | 0.00% | – |
| Q3 2016 | $25,000 | -49.0% | 48,944 | 0.0% | 0.00% | – |
| Q2 2016 | $49,000 | +48.5% | 48,944 | 0.0% | 0.00% | – |
| Q1 2016 | $33,000 | -44.1% | 48,944 | 0.0% | 0.00% | – |
| Q4 2015 | $59,000 | -45.9% | 48,944 | 0.0% | 0.00% | – |
| Q3 2015 | $109,000 | -4.4% | 48,944 | 0.0% | 0.00% | – |
| Q2 2015 | $114,000 | +11.8% | 48,944 | 0.0% | 0.00% | – |
| Q1 2015 | $102,000 | 0.0% | 48,944 | 0.0% | 0.00% | – |
| Q4 2014 | $102,000 | -22.1% | 48,944 | 0.0% | 0.00% | – |
| Q3 2014 | $131,000 | -28.4% | 48,944 | 0.0% | 0.00% | – |
| Q2 2014 | $183,000 | -56.8% | 48,944 | +17.2% | 0.00% | -100.0% |
| Q1 2014 | $424,000 | +20.5% | 41,744 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $352,000 | -10.4% | 41,744 | -1.6% | 0.00% | 0.0% |
| Q3 2013 | $393,000 | -5.5% | 42,444 | 0.0% | 0.00% | 0.0% |
| Q2 2013 | $416,000 | – | 42,444 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,111,590 | $7,876,000 | 3.50% |
| Abingworth LLP | 603,740 | $2,234,000 | 1.04% |
| BVF INC/IL | 862,069 | $3,216,000 | 0.51% |
| SABBY MANAGEMENT, LLC | 922,562 | $3,441,000 | 0.15% |
| TFS CAPITAL LLC | 360,260 | $1,344,000 | 0.11% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 175,980 | $656,000 | 0.04% |
| Tekla Capital Management LLC | 113,100 | $422,000 | 0.04% |
| Visium Asset Management, LP | 598,443 | $2,232,000 | 0.04% |
| A.R.T. Advisors, LLC | 101,905 | $380,000 | 0.02% |
| B. Riley Wealth Management, Inc. | 6,300 | $23,000 | 0.02% |